Has Sleman Khoury, MD received payments from drug or device companies?

Yes. Drug and device makers reported $63,225 in general payments to Sleman Khoury, MD across 1,366 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sleman Khoury, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sleman Khoury, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sleman Khoury, MD

Endocrinology, Diabetes & Metabolism · Southgate, MINPI 1578543849

Payments from drug & device makers

$63,225in general payments, 2019–2025

Across 1,366 payments — averaging $46.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi-aventis U.S. LLC$18K
Johnson & Johnson$12K
Novo Nordisk$9K
Lilly USA, LLC$3K
Ascendis Pharma Endocrinology Inc$3K
Amgen$2K
plus $16K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi-aventis U.S. LLC	58	$17,905
Johnson & Johnson	30	$12,238
Novo Nordisk	207	$9,418
Lilly USA, LLC	182	$3,180
Ascendis Pharma Endocrinology Inc	13	$2,539
Amgen(2 entities)	90	$1,867
Corcept Therapeutics	53	$1,545
Boehringer Ingelheim	76	$1,507
AstraZeneca(2 entities)	53	$1,216
Tandem Diabetes Care, Inc.	36	$984
Dexcom, Inc.	57	$903
AbbVie	41	$847
Bayer	30	$665
Abbott	39	$661
Antares Pharma, Inc.	38	$619
Xeris Pharmaceuticals, Inc.	34	$522
Cequr Corporation	4	$511
Amneal Pharmaceuticals LLC	28	$501
Amarin Pharma, Inc.	21	$364
Neurocrine Biosciences, Inc.	8	$311
Merck	23	$304
Endo Pharmaceuticals Inc.	17	$285
BD	19	$284
Novartis	17	$275
Recordati_rare_diseases_inc.	9	$252
Insulet Corporation	14	$249
Mannkind Corporation	12	$231
Regeneron Healthcare Solutions, Inc.	9	$202
Esperion Therapeutics, Inc.	11	$200
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	9	$193
Ascensia Diabetes Care US Inc.	10	$185
Amryt Pharma Holdings Ltd	10	$181
Radius Health, Inc.	9	$180
Madrigal Pharmaceuticals	7	$147
Ultragenyx Pharmaceutical Inc.	7	$144
Kowa Pharmaceuticals America, Inc.	10	$127
Astellas Pharma US Inc	7	$121
Verity Pharmaceuticals Inc.	6	$120
Pfizer	6	$108
Halozyme Inc	5	$99
Shire North American Group Inc	5	$90
Averitas Pharma Inc.	3	$73
Embecta Corp.	4	$73
Rhythm Pharmaceuticals, Inc.	3	$66
Nevro Corp.	2	$64
Ipsen Biopharmaceuticals, Inc	3	$62
Janssen Scientific Affairs, LLC	1	$59
EUSA Pharma (US) LLC	2	$52
Zealand Pharma US, Inc.	3	$51
Medtronic	2	$45
Sequel Med Tech, LLC	2	$41
Chiesi USA, Inc.	2	$41
Nestle Healthcare Nutrition Inc.	3	$38
Eisai Inc.	2	$35
Alvogen Inc	2	$30
GSK	1	$28
GRT US Holding, Inc.	2	$28
Currax Pharmaceuticals LLC	2	$27
Acella Pharmaceuticals, LLC	1	$22
Kyowa Kirin, Inc.	1	$21

How this compares

$63,225 in reported general payments places this provider in the 85th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.

See all endocrinology, diabetes & metabolism providers in Michigan →

Medicare billing

Part B allowed, 2024

$205,444

Medicare patients

799

Services billed

1,945

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Southgate

Nadia KhourySouthgate$33K
Tobias ElseAnn Arbor$3.5M
Elif OralAnn Arbor$2.9M
Jamal HammoudFlint$2.6M
Lowell SchmeltzFarmington Hills$2.3M
George GrunbergerBloomfield Hills$1.9M
Richard AuchusAnn Arbor$1.3M
Ariel BarkanAnn Arbor$553K
Gary EdelsonFarmington Hills$503K
Michael BrennanSaint Clair Shores$433K

See the full list for Michigan →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →